Fusion imaging: A novel staging modality in testis cancer

Journal of Cancer

Volumn 1, Issue 1, 2010, Pages 223-229

  Sterbis, Joseph R ^a   Rice, Kevin R ^a   Javitt, Marcia C ^a   Schenkman, Noah S ^a   Brassell, Stephen A ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Germ cell; Imaging; Positron emission tomography; Staging; Testis cancer

Indexed keywords

TUMOR MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FIBROSIS; FOLLOW UP; FUSION IMAGING; HUMAN; HUMAN TISSUE; IMAGING; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; METABOLIC PARAMETERS; MICROMETASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; TESTIS CANCER;

EID: 80955129116     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.1.223     Document Type: Article

References (24)

1. American Cancer Society: Cancer Facts & Figures 2009. Atlanta, GA: American Cancer Society, 2009.
2. Fernandez EB, Moul JW, Foley JP, Colon E, McLeod DG. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology. 1994; 44: 548-52.
3. McLeod DG, Weiss RB, Stablein DM, et al. Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol. 1991; 145: 1178-83.
4. Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology. 1999; 53: 808-11.
5. Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Partridge SE, Huddart RA. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med. 2000; 27: 590-4.
6. Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Harper PG, Huddart RA. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer. 2000; 83: 863-9.
7. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006; 238: 405-22.
8. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003; 348: 2500-7.
9. Metser U, Goor O, Lerman H, Naparstek E, Even-Sapir E. PET-CT of extranodal lymphoma. AJR Am J Roentgenol. 2004; 182: 1579-86.
10. Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med. 2003; 44: 1797-803.
11. Spermon JR, Roeleveld TA, van der Poel HG, et al. Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors. Urology. 2002; 59: 923-9.
12. Horwich A, Alsanjari N, A'Hern R, Nicholls J, Dearnaley DP, Fisher C. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer. 1992; 65: 775-8.
13. Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol. 1996; 14: 1637-41.
14. De Santis M, Bokemeyer C, Becherer A, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol. 2001; 19: 3740-4.
15. Cremerius U, Wildberger JE, Borchers H, et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients. Urology. 1999; 54: 900-4.
16. Lassen U, Daugaard G, Eigtved A, Hojgaard L, Damgaard K and Rorth M: Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging. 2003;30: 396-402.
17. Hilton S, Herr HW, Teitcher JB, Begg CB and Castellino RA: CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol. 1997;169: 521-5.
18. Sugawara Y, Zasadny KR, Grossman HB, Francis IR, Clarke MF and Wahl RL: Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology. 1999;211: 249-56.
19. Cremerius U, Effert PJ, Adam G, Sabri O, Zimmy M, Wagenk-necht G, Jakse G and Buell U: FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med. 1998;39: 815-22.
20. Kumar R, Zhuang H and Alavi A: PET in the management of urologic malignancies. Radiol Clin North Am 2004. 42: 1141-53.
21. Jochelson MS, Garnick MB, Balikian JP and Richie JP: The effi-cacy of routine whole lung tomography in germ cell tumors. Cancer. 1984;54: 1007-9.
22. Singh J and Daftary A: Iodinated contrast media and their ad-verse reactions. J Nucl Med Technol. 2008;36: 69-74.
23. American College of Radiology. Manual on Contrast Media, Version 6. US: American College of Radiology, 2008.
24. Lin E, Abass A. PET and PET/CT, A Clinical Guide. New York, NY: Thieme Medical Publishers, 2005.